-+ 0.00%
-+ 0.00%
-+ 0.00%

MERCK RECEIVES POSITIVE EU CHMP OPINION FOR KEYTRUDA® (PEMBROLIZUMAB) PLUS PADCEV® (ENFORTUMAB VEDOTIN-EJFV) AS PERIOPERATIVE TREATMENT FOR ADULTS WITH RESECTABLE MUSCLE-INVASIVE BLADDER CANCER (MIBC)

路透·09/18/2026 10:55:00

登录查看新闻详情